¾ÅÖÝÓ°Ôº

As active pharmaceutical ingredients (APIs) become increasingly complex and process development timelines continue to compress, the pharmaceutical industry requires more efficient and sustainable synthetic approaches for intermediate and API manufacture.  In 2026, the use of enzymes in intermediate and API synthesis has become routine across much of the biopharmaceutical sector, supporting both incremental improvements to individual process steps and, in some cases, complete route redesigns. Since 2002, Codexis has been at the forefront of this transformation, enabling pharmaceutical partners to develop robust, scalable processes that leverage the power of engineered enzymes that have been tailored for the desired processes. This presentation will provide a brief overview of Codexis’ enzyme engineering approach and highlight representative examples demonstrating its impact on efficiency, sustainability, and supply chain resilience.